MindMed’s (MNMD) Nasdaq debut Tuesday made it the second psychedelic drug developer to be listed on a major U.S. stock exchange. UK-based Compass Pathways (CMPS) went public on the Nasdaq in September, while last week Peter Thiel-backed ATAI Life Sciences filed for an IPO. Just a year ago, New York-based MindMed was a penny stock on the over-the-counter market. Shares fell 29% in their first day of trading on the Nasdaq, but that’s after they ran up 65% Friday and 33% Monday on the OTCQB… Source link
Read More »MindMed Begins Trading on Nasdaq
TipRanks Raymond James: These 3 Stocks Have Over 100% Upside on the Horizon We’re now in the heart of earnings season, and investors are paying close attention as companies report their financial results from the first quarter of 2021. It’s a routine, in some ways, but in others, there has never been an earnings season quite like this. It’s the first one post-pandemic, but perhaps more importantly, the results are coming out during a time of nearly unprecedented government stimulus… Source link
Read More »